 |
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評論] [本類其他產(chǎn)品] [本類其他供應商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷售商： 上海皓元生物醫(yī)藥科技有限公司 | 查看該公司所有產(chǎn)品 >> |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。
ResminostatCAS No. : 864814-88-0
MCE 國際站：Resminostat
產(chǎn)品活性：Resminostat (RAS2410; 4SC-201) 是一種有效的 HDAC1，HHDAC3 和 HDAC6 抑制劑，IC50 值分別為 42.5，50.1，71.8 nM，同時對 HDAC8 有較弱的抑制作用，IC50 值為 877 nM。
研究領域：Cell Cycle/DNA Damage | Epigenetics
作用靶點：HDAC
In Vitro: Resminostat (RAS2410; 4SC-201; 5 μM) induces histone acetylation in myeloma cells. Resminostat hydrochloride displays a substrate competitive binding mode with a mean Ki value of 27 nM. Resminostat hydrochloride (5 μM) induces histone hyperacetylation in myeloma cells. Resminostat inhibits cell growth, induces apoptosis and inhibits MM cell proliferation. Resminostat (5 μM) also modulates expression of bcl-2 family proteins and inhibits Akt pathway signalling downstream of Akt. Resminostat exerts synergistic activity against myeloma cells when combined with common and new anti-myeloma agents.
Resminostat inhibits cell growth in head and neck squamous cell carcinoma cell lines, with IC50s ranging from 0.775 μM to 1.572 μM (IC50 for SCC25: 0.775 μM; CAL27: 1.572 μM; and FaDu: 0.899 μM). Resminostat (1.25 and 2.5 μM) has a synergistic effect with irradiation on HNSCC cell lines. Resminostat in combination with cisplatin induces a downregulation of survivin. However, Resminostat shows no effect on Mcl-1 and p-AKT expression.
Resminostat reduces viability of HCC cells with the co-treatment of AZD-2014, with IC50s ranging from 0.89 ± 0.12 μM to 0.07 ± 0.01 μM.
相關產(chǎn)品：Trichostatin A | 4-Phenylbutyric acid | Valproic acid | Entinostat | Sulforaphane | Romidepsin | RGFP966 | Tasquinimod | Corin | Tacedinaline | Dacinostat | ITSA-1 | SIS17 | Tubastatin A Hydrochloride | WT-161 | Givinostat hydrochloride monohydrate | Pyroxamide | Scriptaid | BRD-6929 | Bufexamac | HDAC8-IN-1 | Sinapinic acid | Apicidin | BML-210 | HDACs/mTOR Inhibitor 1 | M344 | Droxinostat | CG347B
品牌介紹:
• MCE (MedChemExpress) 擁有數(shù)百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質(zhì)小分子活性化合物；
• 10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領域；
• 設有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
• Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球最新的活性化合物；
• 與世界各大制藥公司及知名科研機構建立了長期的合作。
